Anti-Von Willebrand Factor antibody [EPSISR15] (ab154193)


  • Product name
    Anti-Von Willebrand Factor antibody [EPSISR15]
    See all Von Willebrand Factor primary antibodies
  • Description
    Rabbit monoclonal [EPSISR15] to Von Willebrand Factor
  • Host species
  • Tested applications
    Suitable for: Flow Cyt, WB, ICC/IFmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Synthetic peptide corresponding to residues in human Von Willebrand Factor (P04275)

  • Positive control
    • Human serum, Human plasma, HepG2 cells
  • General notes

    Mouse, Rat: We have preliminary internal testing data to indicate this antibody may not react with these species. Please contact us for more information.


    Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMab® patents

    We are constantly working hard to ensure we provide our customers with best in class antibodies. As a result of this work we are pleased to now offer this antibody in purified format. We are in the process of updating our datasheets. The purified format is designated 'PUR' on our product labels. If you have any questions regarding this update, please contact our Scientific Support team.

    This product is a recombinant rabbit monoclonal antibody.



Our Abpromise guarantee covers the use of ab154193 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
Flow Cyt 1/200.
WB 1/1000 - 1/10000. Predicted molecular weight: 309 kDa.
ICC/IF 1/250 - 1/500.


  • Function
    Important in the maintenance of hemostasis, it promotes adhesion of platelets to the sites of vascular injury by forming a molecular bridge between sub-endothelial collagen matrix and platelet-surface receptor complex GPIb-IX-V. Also acts as a chaperone for coagulation factor VIII, delivering it to the site of injury, stabilizing its heterodimeric structure and protecting it from premature clearance from plasma.
  • Tissue specificity
  • Involvement in disease
    Defects in VWF are the cause of von Willebrand disease (VWD) [MIM:277480]. VWD defines a group of hemorrhagic disorders in which the von Willebrand factor is either quantitatively or qualitatively abnormal resulting in altered platelet function. Symptoms vary depending on severity and disease type but may include prolonged bleeding time, deficiency of factor VIII and impaired platelet adhesion. Type I von Willebrand disease is the most common form and is characterized by partial quantitative plasmatic deficiency of an otherwise structurally and functionally normal Willebrand factor; type II is associated with a qualitative deficiency and functional anomalies of the Willebrand factor; type III is the most severe form and is characterized by total or near-total absence of Willebrand factor in the plasma and cellular compartments, also leading to a profound deficiency of plasmatic factor VIII.
  • Sequence similarities
    Contains 1 CTCK (C-terminal cystine knot-like) domain.
    Contains 4 TIL (trypsin inhibitory-like) domains.
    Contains 3 VWFA domains.
    Contains 3 VWFC domains.
    Contains 4 VWFD domains.
  • Domain
    The von Willebrand antigen 2 is required for multimerization of vWF and for its targeting to storage granules.
  • Post-translational
    All cysteine residues are involved in intrachain or interchain disulfide bonds.
    N- and O-glycosylated.
  • Cellular localization
    Secreted. Secreted > extracellular space > extracellular matrix. Localized to storage granules.
  • Information by UniProt
  • Database links
  • Alternative names
    • Coagulation factor VIII antibody
    • Coagulation factor VIII VWF antibody
    • F8VWF antibody
    • Factor VIII related antigen antibody
    • von Willebrand antigen 2 antibody
    • von Willebrand antigen II antibody
    • Von Willebrand disease antibody
    • VWD antibody
    • vWF antibody
    • VWF_HUMAN antibody
    see all


  • Immunocytochemistry/ Immunofluorescence analysis of HepG2 (Human hepatocellular carcinoma epithelial cell) cells labeling Von Willebrand Factor with Purified ab154193 at 1:250 dilution. Cells were fixed in 4% Paraformaldehyde and permeabilized with 0.1% tritonX-100. Cells were counterstained with Ab195889 Anti-alpha Tubulin antibody [DM1A] - Microtubule Marker (Alexa Fluor ® 594) 1:200 (2.5 μg/ml). ab150077 Goat anti rabbit IgG(Alexa Fluor ® 488) was used as the secondary antibody at 1:1000 dilution. DAPI nuclear counterstain. PBS instead of the primary antibody was used as the secondary antibody only control.
  • Flow cytometry analysis of HepG2 (Human hepatocellular carcinoma epithelial cell) cells labeling Von Willebrand Factor (red) with purified ab154193 at a 1/130 dilution (10ug/mL). Cells were fixed with 4% paraformaldehyde and permeabilized with 90% methanol. A goat anti rabbit IgG (Alexa Fluor® 488) (ab150077) was used as the secondary antibody at a 1/2000 dilution. Black - Rabbit monoclonal IgG (Black) (ab172730). Blue (unlabeled control) - Cell without incubation with primary antibody and secondary antibody (Blue).

  • Anti-Von Willebrand Factor antibody [EPSISR15] (ab154193) at 1/1000 dilution (purified) + Human plasma lysates at 15 µg

    Goat Anti-Rabbit IgG (HRP) with minimal cross-reactivity with human IgG at 1/2000 dilution

    Predicted band size: 309 kDa
    Observed band size: 309 kDa

    Blocking and diluting buffer: 5% NFDM/TBST.

  • All lanes : Anti-Von Willebrand Factor antibody [EPSISR15] (ab154193) at 1/1000 dilution (unpurified)

    Lane 1 : Human serum
    Lane 2 : Human plasma

    Lysates/proteins at 10 µg per lane.

    Predicted band size: 309 kDa

  • Immunofluorescent staining of HepG2 cells labeling Von-Willebrand-Factor with unpurified ab154193 at 1/250 dilution.


This product has been referenced in:
  • Zhu X  et al. von Willebrand factor contributes to poor outcome in a mouse model of intracerebral haemorrhage. Sci Rep 6:35901 (2016). ICC/IF ; Mouse . Read more (PubMed: 27782211) »
  • Liu Y  et al. The role of von Willebrand factor as a biomarker of tumor development in hepatitis B virus-associated human hepatocellular carcinoma: a quantitative proteomic based study. J Proteomics 106:99-112 (2014). WB, IHC ; Human . Read more (PubMed: 24769235) »

See all 2 Publications for this product

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab154193.
Please use the links above to contact us or submit feedback about this product.


Sign up